BioSpace News Archive

Drug Development

Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy

Sierra Oncology reported preclinical data supporting the ongoing clinical development strategy for its Chk1 inhibitor, SRA737.

October 30, 2017

·

7 min read

Business

PDL BioPharma Announces Settlement Agreement with Valeant

PDL BioPharma today announced that on October 27, 2017, PDL and Depomed entered into a settlement agreement with Valeant Pharmaceuticals International and its indirect subsidiary Valeant that resolves all matters addressed in the lawsuit filed by Depomed on September 7, 2017.

October 30, 2017

·

2 min read

Biotech Bay

Episona Launches International Sales of Epigenetic Test for Male Infertility

Episona announced today that it has expanded online sales of Seed, its at-home test for evaluating male infertility and poor embryo development, to consumers globally, with a few exceptions such as China.

October 30, 2017

·

2 min read

Bio NC

vTv Therapeutics to Present on Azeliragon at the 10th Clinical Trials on Alzheimer’s Disease (CTAD)

vTv is currently studying azeliragon in two identical, randomized, double-blind, placebo-controlled Phase 3 trials investigating its efficacy as a potential treatment of mild Alzheimer’s disease.

October 30, 2017

·

5 min read

Business

Medizone’s AsepticSure Disinfection System Introduced to Nordic Region

Medizone and Aglon a/s today announced that they have entered into an agreement for the introduction and distribution of AsepticSure in the Nordic Region.

October 30, 2017

·

3 min read

Golden Meditech Announces the Proposed Voluntary Delisting of TDR on TWSE

Golden Meditech today announces that the board of directors of the Company resolved to initiate an application for the voluntary delisting of the TDR from the TWSE, the repurchase of TDR resulting from the Voluntary Delisting and the TDR conversion offer.

October 30, 2017

·

2 min read

Drug Development

Siamab Therapeutics Presents New Preclinical Safety Data for ST1 Antibody Therapeutics Program at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

These results add to the company’s efficacy data findings showing that its anti-STn antibody therapeutics inhibit tumor progression in cell-line-derived and patient-derived xenograft (PDX) ovarian cancer and pancreatic cancer mouse models, with complete regression observed in some treatment arms.

October 30, 2017

·

4 min read

Drug Development

SetPoint Medical Presents Early Data Showing Bioelectronic Medicine Accelerates Remyelination in Animal Model of Multiple Sclerosis

These results show promise for a possible bioelectronic treatment for MS and lay the groundwork for further studies by SetPoint.

October 30, 2017

·

3 min read

Therapix Biosciences Initiates Non-clinical Studies for its Antibacterial Program in Collaboration With the Weizmann Institute of Science and Tel Aviv Sourasky Medical Center

Therapix has initiated non-clinical studies to evaluate the efficacy of its proprietary compound THX-150, a pharma composition of dronabinol in collaboration with the Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center.

October 30, 2017

·

7 min read

Business

Endo Announces Certain Preliminary Financial Results for Third-Quarter 2017 and Affirms Selected 2017 Financial Guidance

Endo International today announced certain preliminary results for the quarter ended September 30, 2017 and also affirmed that for the twelve months ending December 31, 2017, the Company expects revenues to be between $3.38B and $3.53B.

October 30, 2017

·

15 min read